Helicobacter pylori eradication protocols

Exciting Progress | Gritgen Therapeutics Completed Patients Enrollment in China’s First Gene Therapy Investigator-Initiated Trial for Hemophilia A and also Achieved the First Patient Dosed in China Phase I Trial in Patients with Severe Hemophilia A

Retrieved on: 
Thursday, November 16, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, Helicobacter pylori eradication protocols, Safety, Therapy, IIT, Haemophilia, Haemophilia A, Pharmaceutical industry, Patient

GS1191, is now the first one completing patient enrollment for IIT study in China.

Key Points: 
  • GS1191, is now the first one completing patient enrollment for IIT study in China.
  • Gritgen also announced that the first patient has been dosed in the China Phase I trial (Protocol No.
  • View the full release here: https://www.businesswire.com/news/home/20231105390422/en/
    Gritgen Therapeutics Achieved the First Patient Dosed in China Phase I Trial in Patients with Severe Hemophilia A.
  • The first patient has been dosed in the China Phase 1 trial on Aug. 2, 2023.

RedHill Biopharma Presents New Data from Talicia®’s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori Eradication

Retrieved on: 
Monday, October 26, 2020
Infectious causes of cancer, Health sciences, Health, Helicobacter pylori, Clinical medicine, Helicobacter pylori eradication protocols, Clarithromycin, Therapy, Rifabutin

The Company also presented data highlighting the emerging patterns of H. pylori resistance to antibiotics used in current standard-of-care therapies.

Key Points: 
  • The Company also presented data highlighting the emerging patterns of H. pylori resistance to antibiotics used in current standard-of-care therapies.
  • This analysis of data from the Talicia Phase 3 studies looked at the cure rates of physician-directed standard-of-care therapy for persistent H. pylori infection.
  • Because H. pylori treatment is largely empiric, it is important that physicians prescribe a first-line regimen with the highest probability of successful eradication.
  • A treatment regimen that does not contain clarithromycin, such as low dose rifabutin-based therapy, is a good first-line option to consider for H. pylori eradication.

New Chinese Research Finds Daily Cranberry Intake Associated with Reduced H. pylori Infection Rates

Retrieved on: 
Tuesday, August 18, 2020
Cancer, Medical specialties, Clinical medicine, Infectious causes of cancer, Helicobacter pylori, Helicobacter, Helicobacter pylori eradication protocols, Saccharomyces boulardii

The study included 522 H. pylori-positive Chinese adults between the ages of 18-60 that have never previously received antibiotic therapy for H. pylori infection.

Key Points: 
  • The study included 522 H. pylori-positive Chinese adults between the ages of 18-60 that have never previously received antibiotic therapy for H. pylori infection.
  • Additional research is needed to further explore any bacterial eradication effects of cranberry on H. pylori.
  • pylori, especially in China where endemic infection and gastric cancer rates are high.6 More research is needed to determine broader effects of cranberry juice andH.
  • Suppression of Helicobacter pylori infection by daily cranberry intake: A double-blind, randomized, placebo-controlled trial.

New Chinese Research Finds Daily Cranberry Intake Associated with Reduced H. pylori Infection Rates

Retrieved on: 
Tuesday, August 18, 2020
Cancer, Medical specialties, Clinical medicine, Infectious causes of cancer, Helicobacter pylori, Helicobacter, Helicobacter pylori eradication protocols, Saccharomyces boulardii

The study included 522 H. pylori-positive Chinese adults between the ages of 18-60 that have never previously received antibiotic therapy for H. pylori infection.

Key Points: 
  • The study included 522 H. pylori-positive Chinese adults between the ages of 18-60 that have never previously received antibiotic therapy for H. pylori infection.
  • Additional research is needed to further explore any bacterial eradication effects of cranberry on H. pylori.
  • pylori, especially in China where endemic infection and gastric cancer rates are high.6 More research is needed to determine broader effects of cranberry juice andH.
  • Suppression of Helicobacter pylori infection by daily cranberry intake: A double-blind, randomized, placebo-controlled trial.

RedHill Biopharma Announces Publication of Talicia® Pivotal Phase 3 Study Results in Annals of Internal Medicine

Retrieved on: 
Tuesday, May 5, 2020
Infectious causes of cancer, RTT, Medicine, Helicobacter pylori, Clinical medicine, Health, Comparator, Rifabutin, Helicobacter pylori eradication protocols

Results demonstrated the added rifabutin benefit with 83.8% eradication of H. pylori infection with Talicia vs. 57.7% in the active comparator arm (ITT analysis, p

Key Points: 
  • Results demonstrated the added rifabutin benefit with 83.8% eradication of H. pylori infection with Talicia vs. 57.7% in the active comparator arm (ITT analysis, p
  • No resistance to rifabutin, a key component of Talicia, was detected in the study.
  • The ePoster and accompanying presentation describe key findings from the pharmacokinetic analysis of the pivotal Phase 3 study with Talicia.
  • No resistance to rifabutin, a key component of Talicia, was detected in the pivotal Phase 3 study.

RedHill Biopharma Announces U.S. Commercial Launch of Talicia® for H. pylori Infection

Retrieved on: 
Monday, March 9, 2020
Medical specialties, Medicine, Clinical medicine, RTT, Infectious causes of cancer, Gastroenterology, Helicobacter pylori, Clarithromycin, Helicobacter, Helicobacter pylori eradication protocols, Giaconda

We are delighted to announce the availability of Talicia in pharmacies nationwide - the first new FDA-approved drug to combat H. pylori infection in over a decade, said Rick Scruggs, Chief Commercial Officer of RedHill.

Key Points: 
  • We are delighted to announce the availability of Talicia in pharmacies nationwide - the first new FDA-approved drug to combat H. pylori infection in over a decade, said Rick Scruggs, Chief Commercial Officer of RedHill.
  • Talicia is the only rifabutin-based therapy approved for the treatment of H. pylori infection and is designed to address the high and growing resistance of H. pylori bacteria to clarithromycin-based standard-of-care therapies.
  • In November 2019, Talicia was approved by the U.S. FDA for the treatment of H. pylori infection in adults.
  • RedHill promotes the gastrointestinal drugs Talicia for the treatment of Helicobacter pylori (H. pylori) infection in adults and Aemcolo for the treatment of travelers diarrhea12.

RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults

Retrieved on: 
Monday, November 4, 2019
Helicobacter pylori, Health, Infectious causes of cancer, Medicine, RTT, Articles, Pharmaceuticals policy, Clarithromycin, Rifabutin, Antimicrobial resistance, Helicobacter pylori eradication protocols, Bacteria

RedHill expects to launch Talicia in the U.S. in the first quarter of 2020 with its dedicated sales force.

Key Points: 
  • RedHill expects to launch Talicia in the U.S. in the first quarter of 2020 with its dedicated sales force.
  • Talicia is the only rifabutin-based therapy approved for the treatment of H. pylori infection and is designed to address the high resistance of H. pylori bacteria to current clarithromycin-based standard-of-care therapies.
  • Treatment of H. pylori infection has become increasingly difficult due to growing bacterial resistance and the lack of advances in treatment options over the past decade.
  • Talicia offers a new effective treatment option to overcome bacterial resistance and provide optimal efficacy and I believe it could become a recommended first-line standard-of-care treatment for H. pylori infection.

Proton Therapy Market Outlook, Actual & Potential Market, Actual and Potential Candidate for Proton Therapy, List of Proton Therapy Centers, Start of Treatment, Number of Patients Treated, Specifications & Company Analysis - Global Forecast to 2024

Retrieved on: 
Tuesday, July 17, 2018
Medical physics, Radiation therapy, Health, Proton, Medicine, Proton therapy, PROTON Holdings, Therapy, Helicobacter pylori eradication protocols

Globally, the numbers of patients treated with Proton Therapy is very low whereas; the potential candidates for proton therapy are in Millions.

Key Points: 
  • Globally, the numbers of patients treated with Proton Therapy is very low whereas; the potential candidates for proton therapy are in Millions.
  • The increased demand for proton therapy has motivated many prominent cancer centers in the world to provide proton therapy treatment.
  • The report titled "Proton Therapy Market Outlook, Actual & Potential Market, Actual and Potential Candidate for Proton Therapy, List of Proton Therapy Centers, Start of Treatment, Number of Patients Treated, Specifications & Company Analysis - Global Forecast to 2024" provides a comprehensive assessment of the fast-evolving, high-growth Proton Therapy Market.
  • Global List of Proton Therapy Centers (Operational, Under Construction and Planned), Start of Treatment, Specifications, Total Number of Patients Treated - Center Wise Analysis
    Global Proton Therapy Market and Patients Analysis, List of Proton Therapy Centers, Start of Treatment, Total Patients Treated - 28 Country Analysis

United States Proton Therapy Market 2009-2018 & 2024 - Market has Potential to Surpass US$ 16 Billion

Retrieved on: 
Tuesday, April 24, 2018
Radiation therapy, Medical physics, Health, Medicine, Proton, Physics, Proton therapy, Therapy, PROTON Holdings, Indiana University Health Proton Therapy Center, Helicobacter pylori eradication protocols

The growth of proton therapy center in the United States is substantial and the number of new advanced proton therapy center would be launched in forecast time-frame.

Key Points: 
  • The growth of proton therapy center in the United States is substantial and the number of new advanced proton therapy center would be launched in forecast time-frame.
  • By 14 Cancer Types - United States Proton Therapy Market & Patients:
    In this report, we have done comprehensive analysis of proton therapy market and proton therapy patient numbers by 14 cancer/tumor types to understand which cancer type has more or less inclination towards proton therapy technology.
  • Annually Treated Patient Database by Proton Therapy Center in United States:
    In this report, we have covered the number of proton therapy patients treated by each proton therapy center since their inception and till 2017 on annual basis.
  • United States Reimbursement Policy regarding Proton Beam Therapy:
    In this report, we have done complete assessment on the United States proton therapy reimbursement policies.